Trial reportInternational urology and nephrology2026
Analysis of the efficacy of fosfomycin trometamol in preventing biofilm bacterial infection in double-J stents among diabetic patients and the factors associated with infection.
Trial report in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo evaluate the efficacy of fosfomycin trometamol powder (FMT) in preventing biofilm-associated bacterial infections on double-J stents in diabetic patients; to characterize the species distribution and antimicrobial susceptibility patterns of biofilm-forming bacteria isolated from these devices; and to identify clinical and microbiological risk factors associated with such infections-thereby informing evidence-based strategies for infection prevention in this high-risk population.
methodsA total of 100 adult diabetic patients who underwent double-J stent placement at our tertiary care center between June 2024 and June 2025 were prospectively enrolled and randomized in a 1:1 ratio to either an experimental group or a control group (n = 50 per group). Patients in the experimental group received a single oral dose of 3 g FMT on the day before stent insertion and on postoperative days 7 and 15; those in the control group received a single oral dose of 0.5 g levofloxacin (LFX) tablets on the day before stent insertion and on postoperative days 1 and 2. At the time of stent removal, stent surface specimens were collected for quantitative biofilm-forming bacterial culture, species identification, and antimicrobial susceptibility testing. Baseline clinical characteristics, stent-related symptoms, and infection outcomes were systematically recorded. Statistical analysis was conducted using SPSS version 26.0, with two-sided p < 0.05 considered statistically significant.
resultsAmong the 100 diabetic patients with indwelling double-J stents, biofilm-forming bacterial colonization was detected in 24 (24.0%), with significantly lower prevalence in the experimental group (7/50, 14.0%) than in the control group (17/50, 34.0%) (χ
conclusionWhen administered with equivalent dosing frequency (three doses total), FMT was associated with a significantly lower detection rate of biofilm-forming bacteria in double-J stent specimens compared with LFX among diabetic patients. These findings support the preferential use of FMT over LFX for targeted prophylaxis in high-risk diabetic populations and underscore the importance of integrating antimicrobial stewardship-particularly agent selection aligned with local resistance patterns-with proactive management of modifiable risk factors to optimize infection prevention and clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.